|Print Page Close Window|
Interested parties can access a live audio webcast on the Events and Presentations section of BioTime’s website. An archived presentation will be available on the website for 30 days. Conference updates can be found on the LD Micro website and directly via Twitter (@theLDMicro).
BioTime is a clinical-stage biotechnology company focused on the
development and commercialization of novel therapies for the treatment
of degenerative diseases. BioTime’s pipeline is based on two platform
technologies which encompass cell replacement and cell/drug delivery.
BioTime’s lead cell replacement product candidate is OpRegen®,
a retinal pigment epithelium transplant therapy in Phase 2 development
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. BioTime’s lead cell delivery
clinical program is Renevia®, an investigational medical
device being developed as an alternative for whole adipose tissue
transfer procedures. BioTime common stock is traded on the NYSE American
and TASE under the symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter,
BioTime Inc. IR
Solebury Trout IR
© Copyright BioTime, Inc.